News

Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, D.C.

All patients who completed 12 weeks of low-dose maintenance therapy were desensitized to levels of peanut protein beyond the 250-300 mg typically found in one peanut kernel. Low-Dose

Remedy Pharmaceuticals CEO Sven Jacobson said: "Our End-of-Phase 2 meeting was a decisive milestone for the Company as we advance the clinical development of CIRARA.. "We are pleased

Nucala, which is administered once every four weeks by injection, maintained its risk/benefit profile over an extended 52-week period. The company enrolled a total of 651 patients in

Idelvion is the albumin fusion protein that links recombinant coagulation factor IX with recombinant albumin to treat hemophilia B. CSL Behring claims that the drug is the first

The rights were jointly owned by the university, researchers working at UCLA at the time of the discoveries and a research organization. The deal includes potential additional payments

With no available vaccine or treatment modalities, the World Health Organization (WHO) recently declared Zika virus an international public health emergency. Vaxart’s vaccine platform enables delivery of recombinant

Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive

Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve